



# **Evidence Accumulated Regarding Therapeutic strategy of older STEMI patients (EARTH-STEMI) collaborative initiative**

## **The EARTH-STEMI meta-analysis**






# Background



-Several randomized clinical trials (RCTs) investigated the benefit of complete revascularization over culprit-only treatment strategy in patients admitted to hospital for ST-segment elevation myocardial infarction (STEMI).

-These RCTs supported the benefit of complete revascularization strategy in the overall population, but some reports suggested that this could be not confirmed in older STEMI patients.






# Background



- The FIRE trial has been designed to address this clinical question and confirmed that a physiology-guided complete revascularization reduces hard endpoints in elderly patient (aged 75 years and older) patients with myocardial infarction (MI) (both STEMI and no ST-segment elevation MI) and multivessel coronary artery disease.

- The integration of the FIRE findings with that from older STEMI patients from previous RCTs may further contribute to definitively clarify the best revascularization strategy for older STEMI patients.





# Why EARTH-STEMI ?!?



- Mean age of previous RCT is around 62 years old
- A subanalysis from the DANAMI 3 questioned the benefit of complete revasc in older STEMI
- FIRE trial enrolled STEMI and NSTEMI patients
- STEMI subgroup of the FIRE trial is not powered for hard endpoints
- To merge our database will give the definitive answer for older STEMI patients with multivessel disease



# AIM of the meta-analysis



The EARTH-STEMI is a patient-level meta-analysis about patient enrolled in all available RCTs regarding revascularization strategy in **older** patients **with STEMI and multivessel disease**.

The review questions is to assess the superiority of complete versus culprit only revascularization in older patients (aged  $\geq 75$  years) with STEMI and multivessel disease:

- 1) in the composite of all-cause mortality, reinfarction and ischemia-driven revascularization;
- 2) in the composite of cardiovascular death and reinfarction;
- 3) in the occurrence of the singular endpoints (cardiovascular death, all-cause death, myocardial infarction, stroke, major bleedings, contrast-induced acute kidney injury, ischemia-driven revascularization).



# Analysis of subgroups




The following **subgroups** will be analysed:

- Impact of **sex** in complete vs culprit only revascularization in older adults
- Impact of **diabetes** in complete vs culprit only revascularization in older adults
- **Age** (<85 vs >85 years old)
- **Comorbidities** (peripheral artery disease, chronic obstructive pulmonary disease, chronic kidney disease, cancer, stroke, bleeding, BMI, frailty assessment)
- **Non culprit** lesion located on left anterior descending artery vs. different coronary vessel location
- Impact of **time delay to primary PCI**
- **Angiographic** vs. **physiology assessment** of non-culprit coronary lesion




# PRISMA FLOW DIAGRAM



Registered in Prospero with  
identifier: **CRD42022367898**



# The meshed studies







# RESULTS



- **results will be published in the next months...**
- **STAY TUNED!!**

